Erenumab is under clinical development by Amgen and currently in Phase II for Pain. According to GlobalData, Phase II drugs for Pain have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Erenumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Erenumab (Aimovig, Aerinex, Pasurta, Glaseeq) is a human immunoglobulin G2 (IgG2) monoclonal antibody. It is formulated as solution in a single-dose for sub-cutaneous route of administration. Erenumab is indicated for the preventive treatment of migraine in adults.
Erenumab (AMG-334) is under development for the treatment of chronic cluster headache, an episodic migraine and chronic migraine. The drug candidate is administered intravenously or subcutaneously as form an of a solution.
It is under development for rosacea, temporomandibular disorder (TMD) pain, migraine in adults and pediatric patients, persistent headache attributed to mild traumatic brain injury (persistent post-traumatic headache) and trigeminal neuralgia. It was also under development for the treatment of hot flashes associated with menopause and stable angina.
Amgen is a biotechnology company, which discovers, develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in therapeutic areas of cardiovascular, oncology/hematology, inflammation, bone health, neurological disorders and nephrology. The company develops products using advanced human genetics to analyze the difficulties of disease and understand the fundamentals of human biology. Amgen sells products primarily to pharmaceutical wholesale distributors in the US. It also markets certain products directly to consumers through direct-to-consumer channels and through partnerships with other companies. The company has presence in Asia Pacific, Europe, Middle East, North America and Australia. Amgen is headquartered in Thousand Oaks, California, the US.
For a complete picture of Erenumab’s drug-specific PTSR and LoA scores, buy the report here.